Cone Health Family Medicine News You Can Use… Jennifer Otter, PharmD Pete Koval, PharmD Cone Health Family Medicine August 2017

New Drug Approval Vosevi® (sofosbuvir/velpatasvir/ voxilapreviar) for Hepatitis C Virus (HCV) Indicated for adult patients with chronic HCV genotypes 1-6 w/out cirrhosis or w/ mild cirrhosis Vosevi is the first medication approved for HCV patients “who have previously been treated w/ sofosbuvir or other HCV drugs that inhibit NS5A”. 7/13/2017 AP.org

New Drug Approval Tremfya® (guselkumab) is an IL-23 inhibitor monoclonal antibody Indicated for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy $9,684 per dose ($58,100/year – cash price) Comparable to Humira® ($59,200/yr) 7/13/2017 AP.org

New Generic Approval Effient® (prasugrel) has been approved by the FDA in a generic formulation Effient is indicated for acute coronary syndrome to be managed with PCI to reduce the rate of thrombotic cardiovascular events However, it will not be available generically until December 2017 7/12/2017 FDA.gov

New Indication Approval Fycompa® (perampanel) is an AMPA Glutamate Receptor Antagonist Anticonvulsant Indicated for adjunctive use for partial- onset seizures and primary generalized seizures in with epilepsy 12 years of age or older New indication: can now be used as monotherapy 7/26/2017 FDA.gov

Drug Removed From Market Endo Pharmaceuticals agrees to pull abuse-deterrent extended release formulation of oxymorphone (Opana ER) from the market after FDA’s June recommendation A significant shift in the route of abuse (nasal administration to injection) was observed after the product’s reformulation Medscape.com, 7/6/17

New Study Patients taking Proton Pump Inhibitors (PPIs) have 25% increased risk of death than patients taking H2 blockers Study published in BMJ Open Journal Expect to see 1 extra death for every 500 people taking PPIs for one year Researchers found a “graded” relationship between PPI use and risk of death (longer use equates to higher risk) 7/3/2017 CBSNews.com

New Study 2 New Studies Show Negative Impact Of NSAID Use in Vigorous Exercise One study published in Emergency Medical Journal found that ultramathoners using NSAIDs were 18% more likely to experience AKI than non-users Second study showed that NSAIDs may impair muscle repair after strenuous exercise 7/5/2017 NY Times.com

New Study Adding 2nd medicine to treat depression may be better strategy than switching medications Researchers at Yale University found that 29% of patients who took the antipsychotic drug aripiprazole (Abilify®) for 12 weeks, along with their original antidepressant, achieved nearly total remission of their depression symptoms JAMA July 11, 2017